What's fueling the biotech engine—2012 to 2013
Author:
- 9 January 2014
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 32 (1) , 32-39
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML expertsBlood, 2013
- Anthrax drug first antibacterial mAb to win approvalNature Biotechnology, 2013
- Failure to launchNature Biotechnology, 2013
- What's fueling the biotech engine—2011 to 2012Nature Biotechnology, 2012
- What's fueling the biotech engine—2009–2010Nature Biotechnology, 2010
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trialThe Lancet, 2010
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- What's fueling the biotech engine—2008Nature Biotechnology, 2009
- What's fueling the biotech engine—2007Nature Biotechnology, 2008
- What's fueling the biotech engine?Nature Biotechnology, 2007